In short
Arcus Biosciences, Inc. (RCUS) has revenue down 4.3% to $247.0M and net income down 24.7% to -$353.0M year on year. Fisclear flags 2 high-severity risks, led by: Net loss of $353.0M — the company spent more than it earned. Investors should monitor the path to profitability. How we calculate this
Valuation
HealthcareLive · Yahoo FinancePrice
$15.62
$2.2B
52-Week Range
Decision Context
Below-average scores in Quality, Efficiency, Cashflow. The data points to fundamental challenges that outweigh near-term macro considerations.
Based on filing period ending Sept 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.88%
Accommodative
10-Year Treasury
5.13%
2026-10-01
Unemployment
4.2%
Near full employment
CPI Index
336.3
2026-09-01
M2 Money Supply
$23.4T
2026-09-01
The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.
SWOT Analysis — RCUS
Inflationary BoomStrengths
No standout strengths identified from the filing.
Weaknesses
Operating Cash Flow: -$482.0M (-183.5% YoY) — Negative operating cash flow — the business consumed more cash than it produced from operations.
Net Income: -$353.0M (-24.7% YoY) — The company posted a net loss — total expenses exceeded total revenue.
EPS (Diluted): $-3.29 (-4.8% YoY) — Negative EPS — the company recorded a loss on a per-share basis.
Revenue: $247.0M (-4.3% YoY) — Revenue fell 4% — the company generated less from its core operations.
Total Assets: $1.1B (-1.0% YoY) — Total assets shrank 1% — the balance sheet contracted.
R&D spending is 212% of revenue — heavy investment in future growth, but also a drag on current profitability.
Opportunities
No clear opportunities identified at this time.
Threats
Net loss of $353.0M — the company spent more than it earned. Investors should monitor the path to profitability.
Negative operating cash flow of $482.0M — the core business consumed more cash than it generated.
Year-over-Year Changes
Operating Cash Flow
-$482.0M
was -$170.0M
Negative operating cash flow — the business consumed more cash than it produced from operations.
Net Income
-$353.0M
was -$283.0M
The company posted a net loss — total expenses exceeded total revenue.
EPS (Diluted)
$-3.29
was $-3.14
Negative EPS — the company recorded a loss on a per-share basis.
Revenue
$247.0M
was $258.0M
Revenue fell 4% — the company generated less from its core operations.
Total Assets
$1.1B
was $1.1B
Total assets shrank 1% — the balance sheet contracted.
Risk Flags
2 high · 0 medium · 1 low- ⚠ High
Net loss of $353.0M — the company spent more than it earned. Investors should monitor the path to profitability.
- ⚠ High
Negative operating cash flow of $482.0M — the core business consumed more cash than it generated.
- ○ Low
R&D spending is 212% of revenue — heavy investment in future growth, but also a drag on current profitability.
Technical Signals
Daily closes · 1-year dataArcus Biosciences, Inc.: common questions
Is Arcus Biosciences, Inc. profitable?
No. Arcus Biosciences, Inc. reported a net loss of $353M in its latest fiscal year (fiscal 2025).
Is Arcus Biosciences, Inc.'s revenue growing?
No. Revenue fell 4.3% year on year, to $247.0M.
What is Arcus Biosciences, Inc.'s P/E ratio?
Arcus Biosciences, Inc. has no meaningful P/E ratio at the moment, because it lost money over the latest year. P/E only works when earnings are positive.
Does Arcus Biosciences, Inc. pay a dividend?
No dividend is currently expected from Arcus Biosciences, Inc., according to the latest market data.
What are the main risks for Arcus Biosciences, Inc.?
Fisclear's checks flag 2 medium- or high-severity risks. The most serious: Net loss of $353.0M — the company spent more than it earned. Investors should monitor the path to profitability.
Answers are generated from the figures in this report (updated 5 Nov 2026). Information, not investment advice.
Latest News
via FinnhubFiling History — RCUS
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade RCUS
Links open broker research pages. Not an endorsement or recommendation.
Research Arcus Biosciences, Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.